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Graham Rook and Laura Rosa Brunet speculate that stimulation of innate 
immunity with components of saprophytic mycobacteria, lactobacilli and 
certain helminths (the “Old Friends”) will form the basis of treatment in the 
future by driving both specific and bystander immunoregulation. 
 
We expect patterns of disease to change in parallel with economic development, but the 
existence of simultaneous increases in diverse chronic inflammatory disorders came as a 
surprise.  Developed countries have more allergic disorders, more autoimmune disease 
(for example Type 1 diabetes and multiple sclerosis) [1] and more inflammatory bowel 
disease (IBD; ulcerative colitis and Crohn’s disease) [2].  Influenced by the increasing 
incidence of Th2-mediated allergies, but largely unaware of the simultaneous increases in 
the Th1-mediated disorders, workers in the field of allergy developed the concept that 
became known as the Hygiene Hypothesis. This hypothesis, though essentially correct, 
rapidly spawned three untenable interpretations which delayed its acceptance. However 
these have now been shown to be unlikely, and a new interpretation, the “Old Friends” 
mechanism, is looking much more promising. 
 
 First it was suggested that diminished exposure to microorganisms in rich developed 
countries fails to drive Th1 cells, with a consequent over-production of Th2 cells. 
According to this interpretation the critical issue was Th1/Th2 balance.  This notion 
ignored both the simultaneous increases in Th1-mediated chronic inflammatory disorders 
and the presence of IFN-γ both in asthma and in atopic dermatitis.  It is now clear that the 
critical balance is not Th1/Th2 but rather Treg/Teffector. All three groups of chronic 
inflammatory disorder, whether mediated by Th1 or Th2 effectors, are characterised by 
immune responses to forbidden targets. It is the role of regulatory T cells to stop such 
unwanted responses, and the imbalance between Treg and Teffector in allergic individuals 
has now been definitively documented [3]. 
 
Secondly, it was suggested that we must suffer true infections such as tuberculosis or the 
childhood virus infections, in order to be protected from chronic inflammatory disorders.  
This view seems to have arisen spontaneously, with little epidemiological support, and 
does not make evolutionary sense. The childhood virus infections are recent additions to 
mankind’s environment. Several excellent studies have indicated that these infections do 
not protect from allergies [4].  
 
Thirdly there was the view, largely created by the media, that home hygiene itself was in 
some way to blame. Newspaper articles implied that we should avoid standard hygienic 
practices such as bactericidal compounds in our kitchen cutting boards, and interviewers 
tried to make us advise listeners to let their children live in squalor. Again, a detailed 
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So what is left?  Should the Hygiene Hypothesis be rejected?   We suggest that the 
answer lies in the “Old Friends” mechanism. Certain harmless microorganisms that are 
part of our evolutionary history, are recognised as “Old Friends” by the innate immune 
system, so rather than priming aggressive immune responses they prime 
immunoregulation [6], mediated in part by release of IL-10 and TGF-β.  The “Old 
Friends” do this by causing an unusual pattern of maturation of dendritic cells (DC) [7] 
such that these retain the ability to drive regulatory T cells (Treg). This in turn leads to two 
mechanisms that help to control inappropriate inflammation. First, continuing throughput 
of the “Old Friends” causes continuous background activation of the DCreg and of Treg 
specific for the Old Friends themselves. The result is a constant background of bystander 
suppression. Secondly, the presence of DCreg that inevitably sample self, gut contents and 
allergens, leads to the induction of Treg specific for the three groups of chronic 
inflammatory disorder.  These mechanisms are of course aborted when there are 
legitimate “danger” signals.  For example, Treg function can be turned off by appropriate 
“danger signals” in vitro [8].  Viewed in the light of the Old Friends mechanism it 
becomes reasonable that polymorphisms of NOD2 (an intracellular receptor for bacterial 
peptidoglycan) should be linked to increased susceptibility to both Crohn’s disease and 
asthma [9]. It is likely that the particular immunoregulatory disorder that develops in an 
individual deprived of “Old Friends” will depend on other aspects of his genetic 
background and immunological history. 
 
Three groups of organism (lactobacilli, saprophytic environmental mycobacteria, and 
some helminths) have been identified as “Old Friends”, though there will be many others 
[6]. Of these, the saprophytic mycobacterium, M. vaccae, has received the most detailed 
immunological study, and it appears to induce in mice exactly the type of Treg (Tr1) that 
is deficient in allergic humans [3, 10]. The optimum route of exposure to the Old Friends 
is via the gut, a critical site for induction of DCreg and Treg. Each of these organisms is 
active in experimental models of at least 2, sometimes all 3 of the groups of inflammatory 
disorder discussed here, as anticipated if there is a shared underlying mechanism. 
Similarly each of them has been subjected to encouraging clinical trials in allergic 
disorders or IBD (discussed in [6]).  
 
So where is this leading? It is probable that a complex pattern of signals is needed to 
make the innate immune system drive immunoregulation. It needs to be a secret code so 
that pathogens cannot too easily acquire it. So it might be difficult to replace the Old 
Friends with single molecules. Moreover, the particular Old Friend needed to restore 
immunoregulation might depend on the genetic polymorphisms of the individual patient. 
The pharmacogenetics could be complex to solve and expensive to apply to the 
individual.   
 
So there are two extreme solutions; the futuristic one and the practical common sense 
one.  
 
The futuristic solution requires that we identify all the critical molecules and patterns of 
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documents the patient’s genetic polymorphisms, and prescribes a capsule containing a 
cocktail of agonists for receptors within the innate immune system that will optimally 
trigger immunoregulation in that individual. Perhaps this will be possible, but as 
pharmaceutical regulatory requirements get more complex and expensive, the prospect of 
isolating, synthesising and manufacturing a panel of novel agonists, and taking each of 
them, and the mixtures, through the regulatory process is a nightmare. Anyway, why 
recreate organisms that already exist? 
 
The more practical solution is contrary to the thought patterns of the pharmaceutical 
industry in 2004, but more likely to be achieved, and more likely to work. If the Old 
Friends used individually as oral treatments are clinically effective, then the objective is 
achieved. If they are not sufficiently potent, or work only in discrete subsets of patients, 
then capsules that incorporate multiple Old Friends could be developed. Taken daily, 
these would evoke both bystander and specific mechanisms of immunoregulation. Taken 
intermittently they would preferentially evoke immunoregulation by specific Treg. The 
pharmaceutical industry may not be ready for common-sense solutions, but we suspect 
that the public would welcome this approach.  
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